{"Clinical Trial ID": "NCT02413008", "Intervention": ["INTERVENTION 1:", "- 0.005% Estriol Vaginal Gel", "Route: Vaginal. Administration by an applicator deeply inserted into the vagina Dose: 1 g of gel, containing 50 Mg of estriol Dosage: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration", "INTERVENTION 2:", "Placebo Vaginal Gel", "Route: Vaginal. Administration by an applicator inserted deeply into the vagina Dose: 1 g of gel. Dosage: Weeks 1-3: single daily application Weeks 4-12: twice a week administration", "- Placebo"], "Eligibility": ["Incorporation criteria:", "Informed consent in writing before initiating specific protocol procedures.", "Patients should have histological confirmation of mammary adenocarcinoma with stage I-IIIA, documented in a local pathology department.", "The breast tumours should be positive for estrogen and/or progesterone receptors (1% of immunohistochemically coloured tumour cells (IHC) as determined by the local laboratory) with any human epidermal growth factor receptor status 2(HER2).", "A postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH > 40 Milli-units international per millilitre (mIU/ml) or 6 weeks of post-surgical bilateral oophorectomy with or without hysterectomy.", "The patient should receive nonsteroidal anastrozole or letrozole aromatase inhibitors as a treatment for breast cancer in the adjuvant setting for at least 6 months.", "Women with moderate to severe vaginal dryness according to FDA guidelines for drug development in menopausal women (Center for Drug Evaluation and Research, (CDER) Jan 2003) A moderate symptom will be considered if the symptom is present, annoying and annoying, and a severe symptom will be considered if the symptom is present, annoying and annoying, and interferes with the patient's normal activity.", "The performance status of the Eastern Cooperative Oncology Group (ECOG PS) of 0 or 1.", "A suitable bone marrow as defined by the following laboratory values:", "Absolute number of neutrophils (ANC) 1.5 x 109/L.", "\u2014 Platelets (plt) 100 x 109/L.", "Hemoglobin (Hgb) 10 g/dl.", "The patient has an adequate organic function as defined by the following laboratory values:", "Serum creatinine 1.5 x Upper limit of normal (ULN).", "Bilirubine 1.5 \u00d7 ULN.", "- Alkaline phosphatase 2 \u00d7 ULN.", "Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2 \u00d7 ULN.", "- Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study methods.", "- Exclusion criteria:", "Stage IIIB-IV Breast cancer or bilateral breast cancer.", "Treatment with any other current anti-tumour therapy (chemotherapy, anti-Her2...etc) outside NSAID. Pamidronate or Alendronate are allowed.", "\u2022 Previous history of other malignancies within 5 years of entry into the study, with the exception of non-melanoma skin cancer or properly treated cervical in-situ carcinoma.", "A postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.", "* Patients with an endometrial thickness of 4 mm or more, measured by transvaginal ultrasound.", "Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.", "The use of any natural hormone (phytoestrogen) or herbal products for the treatment of menopause symptoms in the last 3 months.", "Current or previous history of thromboembolic disease or coagulopathy.", "Severe cardiovascular or respiratory disease in the previous 6 months.", "- Renal deficiency.", "- carriers of hepatitis B and/or hepatitis C (unless they have normal liver function).", "A known human immunodeficiency virus infection.", "A known hypersensitivity to IASN.", "Other acute or chronic acute medical or psychiatric conditions, or laboratory abnormalities that, in the opinion of the investigator, would pose an excessive risk associated with participating in the study or administration of drugs under study, or that, in the opinion of the investigator, would render the patient inappropriate for entering the study.", "A previous trial treatment for any condition or participation in a clinical trial within 4 weeks of the date of inclusion."], "Results": ["Performance measures:", "Change in serum levels of follicular stimulating hormone (FSH)", "Serum follicular stimulating hormone (HFF) levels relative to natural physiological variability (serigraphic variation)", "Duration of treatment: from baseline to 12 weeks of treatment", "Results 1:", "Title of the arm/group: 0.005% Estriol Vaginal Gel", "Description of the arm/group: Route: Vaginal. Administration by an applicator inserted deeply into the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration", "Total number of participants analysed: 50", "Median (interquartile range)", "Unit of measurement: mIU/ml -2.8 (-13.1 to 7.4)", "Results 2:", "Title of the arm/group: Vaginal gel Placebo", "Description of the arm/group: Route: Vaginal. Administration by an applicator inserted deeply into the vagina Dose: 1 g of gel.", "- Placebo", "Total number of participants analysed: 11", "Median (interquartile range)", "Unit of measurement: mIU/ml 1,4 (-5,4 to 15,7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/50 (2.0%)", "- Lymphoma [1]1/50 (2.0%)", "Adverse Events 2:", "Total: 0/11 (0.00 per cent)", "- Lymphoma [1]0/11 (0.00 %)"]}